🔎 Trials Near Me

Home › Mild Cognitive Impairment › NCT05965518

High-Intensity Exercise to Combat Vascular and Cognitive Dysfunction in Adults With HIV

Recruiting

A Pilot Trial of High-Intensity Exercise to Combat Vascular and Cognitive Dysfunction in Older Adults With HIV

Who can join

Ages 50 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Age 50 years and older
* Sedentary lifestyle, defined as \< 150 min/wk moderate physical activity as assessed by CHAMPS questionnaire
* Neurocognitive Impairment (as assessed using the BRACE+
* Prescribed HIV ART for ≥ 12 months, with no current use of older drugs with established mitochondrial toxicity
* Able to speak, read, and write in English
* Willingness to participate in all study procedures

Exclusion Criteria:

* Diagnosis of mitochondrial disease
* Active substance abuse or factors preventing compliance or safety
* Uncontrolled hypertension, defined as resting BP \> 150/90 mmHG
* Chronic kidney disease
* Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina
* Acute myocardial infarction identified by medical history and ECG
* Pulmonary disease requiring the use of supplemental oxygen
* Poorly controlled diabetes
* Neuropsychologically Intact
* Orthopedic problems that limit ability to perform exercise
* Simultaneous participation in another intervention trial

About the study

This is a single site, randomized exercise trial with individuals at least 50 years of age living with HIV who experience suboptimal cognition. The overall goals of this proposal are to determine whether 16 weeks of structured high-intensity interval training (HIIT) can overcome vascular and cognitive impairments (Aim 1) to a greater extent than continuous moderate exercise. Additionally, investigator will seek to identify barriers to engagement in exercise and the participants' perceptions of the study and exercise interventions (Aim 2). This study will enroll 60 participants in Birmingham, Alabama. Data collection will occur at each visit, with baseline data collected at the initial visit with a 3-month follow-up occurring following completion of the intervention.

What is being tested

Sponsor: University of Alabama at Birmingham · Participants: 60 · Started: Feb 5, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT05965518

Locations in the U.S.

AlabamaUniversity of Alabama at Birmingham, Birmingham

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.